UroGen Pharma Files 8-K
Ticker: URGN · Form: 8-K · Filed: 2024-03-04T00:00:00.000Z
Sentiment: neutral
Topics: regulatory-filing, 8-K
Related Tickers: URGN
TL;DR
UroGen Pharma filed a routine 8-K, no major news.
AI Summary
UroGen Pharma Ltd. filed an 8-K on March 4, 2024, to report on Regulation FD disclosures and financial statements. The filing does not contain specific financial figures or material events beyond the standard reporting requirements.
Why It Matters
This filing indicates UroGen Pharma Ltd. is meeting its regulatory reporting obligations with the SEC, which is standard practice for publicly traded companies.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for regulatory compliance and does not disclose any new material risks or events.
Key Players & Entities
- UroGen Pharma Ltd. (company) — Registrant
- 0001193125-24-056770 (filing_id) — Accession Number
- March 4, 2024 (date) — Filing Date
FAQ
What is the purpose of this 8-K filing?
This 8-K filing serves to report on Regulation FD disclosures and to file financial statements and exhibits as required by the SEC.
What is the exact name of the registrant?
The exact name of the registrant is UroGen Pharma Ltd.
In which jurisdiction was UroGen Pharma Ltd. incorporated?
UroGen Pharma Ltd. was incorporated in Israel.
What is the principal executive office address of UroGen Pharma Ltd.?
The address of the principal executive offices is 400 Alexander Park Drive, 4th Floor, Princeton, New Jersey, 08540.
What is the telephone number for UroGen Pharma Ltd.?
The registrant's telephone number, including area code, is +1 (646) 768-9780.
Filing Stats: 493 words · 2 min read · ~2 pages · Grade level 11.1 · Accepted 2024-03-04 07:00:52
Filing Documents
- d743593d8k.htm (8-K) — 24KB
- d743593dex991.htm (EX-99.1) — 54KB
- g743593ex99_1p10g1.jpg (GRAPHIC) — 238KB
- g743593ex99_1p11g1.jpg (GRAPHIC) — 356KB
- g743593ex99_1p12g1.jpg (GRAPHIC) — 372KB
- g743593ex99_1p13g1.jpg (GRAPHIC) — 247KB
- g743593ex99_1p14g1.jpg (GRAPHIC) — 327KB
- g743593ex99_1p15g1.jpg (GRAPHIC) — 211KB
- g743593ex99_1p16g1.jpg (GRAPHIC) — 282KB
- g743593ex99_1p17g1.jpg (GRAPHIC) — 320KB
- g743593ex99_1p18g1.jpg (GRAPHIC) — 258KB
- g743593ex99_1p19g1.jpg (GRAPHIC) — 303KB
- g743593ex99_1p1g1.jpg (GRAPHIC) — 348KB
- g743593ex99_1p20g1.jpg (GRAPHIC) — 300KB
- g743593ex99_1p21g1.jpg (GRAPHIC) — 220KB
- g743593ex99_1p22g1.jpg (GRAPHIC) — 192KB
- g743593ex99_1p23g1.jpg (GRAPHIC) — 323KB
- g743593ex99_1p24g1.jpg (GRAPHIC) — 193KB
- g743593ex99_1p25g1.jpg (GRAPHIC) — 246KB
- g743593ex99_1p26g1.jpg (GRAPHIC) — 243KB
- g743593ex99_1p27g1.jpg (GRAPHIC) — 357KB
- g743593ex99_1p28g1.jpg (GRAPHIC) — 309KB
- g743593ex99_1p29g1.jpg (GRAPHIC) — 361KB
- g743593ex99_1p2g1.jpg (GRAPHIC) — 509KB
- g743593ex99_1p30g1.jpg (GRAPHIC) — 351KB
- g743593ex99_1p31g1.jpg (GRAPHIC) — 290KB
- g743593ex99_1p32g1.jpg (GRAPHIC) — 99KB
- g743593ex99_1p33g1.jpg (GRAPHIC) — 343KB
- g743593ex99_1p34g1.jpg (GRAPHIC) — 329KB
- g743593ex99_1p35g1.jpg (GRAPHIC) — 282KB
- g743593ex99_1p36g1.jpg (GRAPHIC) — 372KB
- g743593ex99_1p37g1.jpg (GRAPHIC) — 295KB
- g743593ex99_1p38g1.jpg (GRAPHIC) — 162KB
- g743593ex99_1p39g1.jpg (GRAPHIC) — 259KB
- g743593ex99_1p3g1.jpg (GRAPHIC) — 395KB
- g743593ex99_1p40g1.jpg (GRAPHIC) — 235KB
- g743593ex99_1p41g1.jpg (GRAPHIC) — 368KB
- g743593ex99_1p42g1.jpg (GRAPHIC) — 211KB
- g743593ex99_1p43g1.jpg (GRAPHIC) — 195KB
- g743593ex99_1p44g1.jpg (GRAPHIC) — 181KB
- g743593ex99_1p45g1.jpg (GRAPHIC) — 210KB
- g743593ex99_1p46g1.jpg (GRAPHIC) — 229KB
- g743593ex99_1p47g1.jpg (GRAPHIC) — 205KB
- g743593ex99_1p48g1.jpg (GRAPHIC) — 228KB
- g743593ex99_1p49g1.jpg (GRAPHIC) — 357KB
- g743593ex99_1p4g1.jpg (GRAPHIC) — 263KB
- g743593ex99_1p50g1.jpg (GRAPHIC) — 250KB
- g743593ex99_1p51g1.jpg (GRAPHIC) — 159KB
- g743593ex99_1p52g1.jpg (GRAPHIC) — 200KB
- g743593ex99_1p53g1.jpg (GRAPHIC) — 228KB
- g743593ex99_1p54g1.jpg (GRAPHIC) — 393KB
- g743593ex99_1p55g1.jpg (GRAPHIC) — 331KB
- g743593ex99_1p56g1.jpg (GRAPHIC) — 359KB
- g743593ex99_1p5g1.jpg (GRAPHIC) — 300KB
- g743593ex99_1p6g1.jpg (GRAPHIC) — 332KB
- g743593ex99_1p7g1.jpg (GRAPHIC) — 221KB
- g743593ex99_1p8g1.jpg (GRAPHIC) — 304KB
- g743593ex99_1p9g1.jpg (GRAPHIC) — 319KB
- 0001193125-24-056770.txt ( ) — 21939KB
- urgn-20240304.xsd (EX-101.SCH) — 3KB
- urgn-20240304_lab.xml (EX-101.LAB) — 18KB
- urgn-20240304_pre.xml (EX-101.PRE) — 11KB
- d743593d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibit No. Description 99.1 Company Presentation, dated March 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: March 4, 2024 UROGEN PHARMA LTD. By: /s/ Don Kim Don Kim Chief Financial Officer